← 治験一覧に戻る
原因不明の塞栓性脳卒中（ESUS）を最近発症した患者における脳卒中の二次予防および全身性塞栓症の予防におけるリバーロキサバンとアスピリンの比較
基本情報
- NCT ID
- NCT02313909
- ステータス
- 中止
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 7,213
- 治験依頼者名
- Bayer
概要
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study will compare 2 blood thinners. Patients will be randomly assigned to either Rivaroxaban 15 mg or Aspirin 100 mg and the study is intended to show, if patients given rivaroxaban have fewer blood clots in the brain (stroke) or in other blood vessels.
対象疾患
Stroke
介入
Rivaroxaban (Xarelto, BAY59-7939)(DRUG)
Acetylsalicylic acid (Aspirin, BAY1019036)(DRUG)
Rivaroxaban-Placebo(OTHER)
Aspirin-Placebo(OTHER)